Literature DB >> 19523966

Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels.

M H Selina Mok1, Anne-Cécile Fricker, Annette Weil, James N C Kew.   

Abstract

To better understand the effects of the tryptophan metabolite kynurenic acid (kynA) in the brain, we characterised its actions at five ligand-gated ion channels: NMDA, AMPA, GABA(A), glycine and alpha7 nicotinic acetylcholine receptors. Using whole-cell patch-clamp recordings, we found that kynA was a more potent antagonist at human NR1a/NR2A compared with NR1a/NR2B receptors (IC(50): 158 muM and 681 muM, respectively; in 30 muM glycine). KynA inhibited AMPA-evoked currents to a similar degree in cultured hippocampal neurons and a human GluR2(flip/unedited) cell line (IC(50): 433 and 596 muM, respectively) and at higher concentrations, kynA also inhibited the strychnine-sensitive glycine receptor ( approximately 35% inhibition by 3 mM kynA). Interestingly, kynA inhibited the peak amplitude (IC(50): 2.9 mM for 10 muM GABA) and slowed the decay kinetics of GABA-evoked currents in cultured neurons. In contrast, we found that kynA (1-3 mM) had no effect on ACh-evoked, methyllycaconitine (MLA)-sensitive currents in a human alpha7 nicotinic receptor (nAChR) cell line, rat hippocampal neurons in primary culture or CA1 stratum radiatum interneurons in rat brain slices. However, DMSO (>1%) did inhibit alpha7 nAChR-mediated currents. In conclusion, kynA is an antagonist at NMDA, AMPA and glycine receptors and a modulator of GABA(A) receptors, but we find no evidence for any effect of kynA at the alpha7 nAChR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523966     DOI: 10.1016/j.neuropharm.2009.06.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  27 in total

1.  Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Howard M Eisenberg; Yasushi Kajii; Robert Schwarcz; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

2.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

Review 3.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

Review 4.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

Review 5.  The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Authors:  Raeesah Maqsood; Trevor W Stone
Journal:  Neurochem Res       Date:  2016-08-23       Impact factor: 3.996

6.  DCyFIR: a high-throughput CRISPR platform for multiplexed G protein-coupled receptor profiling and ligand discovery.

Authors:  N J Kapolka; G J Taghon; J B Rowe; W M Morgan; J F Enten; N A Lambert; D G Isom
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-20       Impact factor: 11.205

Review 7.  Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior.

Authors:  Francesca M Notarangelo; Ana Pocivavsek
Journal:  Neuropharmacology       Date:  2016-03-02       Impact factor: 5.250

8.  Reduction of brain kynurenic acid improves cognitive function.

Authors:  Rouba Kozak; Brian M Campbell; Christine A Strick; Weldon Horner; William E Hoffmann; Tamas Kiss; Douglas S Chapin; Dina McGinnis; Amanda L Abbott; Brooke M Roberts; Kari Fonseca; Victor Guanowsky; Damon A Young; Patricia A Seymour; Amy Dounay; Mihaly Hajos; Graham V Williams; Stacy A Castner
Journal:  J Neurosci       Date:  2014-08-06       Impact factor: 6.167

Review 9.  Small molecule inhibitors in the treatment of cerebral ischemia.

Authors:  Jerry J Flores; Yang Zhang; Damon W Klebe; Tim Lekic; Weiling Fu; John H Zhang
Journal:  Expert Opin Pharmacother       Date:  2014-02-04       Impact factor: 3.889

Review 10.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.